Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
m (Stage 3: Technically Confirmed Profiles)
Line 4: Line 4:
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 +
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.5 Dec-2014]]
 +
:* [[Media:UPICT Oncologic FDG-PETCTProtocol 5-20-14.pdf|UPICT Protocol - Oncology FDG-PET CT 05-20-2014]]
  
'''UPICT protocol'''
 
*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Oncology FDG-PET CT Protocol, v2.5 Dec-2014]]
 
*[[Media:UPICT Oncologic FDG-PETCTProtocol 5-20-14.pdf|UPICT Oncology FDG-PET CT Protocol 05-20-2014]]
 
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017]]  
+
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]  
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]]
+
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 +
 
 
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
 
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
 
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
 
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
Line 32: Line 32:
 
:*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|Spreadsheet: Small Nodule Profile References - Accuracy]]  
 
:*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|Spreadsheet: Small Nodule Profile References - Accuracy]]  
 
:*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|Spreadsheet: Small Nodule Profile References - Precision]]
 
:*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|Spreadsheet: Small Nodule Profile References - Precision]]
 +
  
 
==Statements of Endorsement==
 
==Statements of Endorsement==

Revision as of 18:11, 21 September 2017

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Stage 3: Technically Confirmed Profiles


Stage 2: Consensus Profiles


Stage 1: Public Comment Profiles

The following Profiles are open for Public Comment:

Please submit all public comments through the following online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; you may submit additional forms as necessary)


Public Comment closed for the following Profiles (comment resolution is currently underway):


Statements of Endorsement


See Also